Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.40+0.40 (+2.22%)
Close on Nov 18, 2026Market cap $2.94BP/E –Yield –
Denali Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.51M | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
See a number that looks wrong?